New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
08:06 EDTNVIVInvivo Therapeutics receives notice of allowance from USPTO
InVivo Therapeutics Holdings Corp. announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application No. 14/177,888, titled “Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries”. The application covers InVivo’s Neuro-Spinal Scaffold, which is currently being studied in a pilot clinical trial, and its Neuro-Spinal Scaffold combined with stem cells, which is being developed for the treatment of chronic spinal cord injury. InVivo is the exclusive licensee of this intellectual property for spinal cord injury and other indications through a license with Boston Children’s Hospital and the Massachusetts Institute of Technology. A notice of allowance from the USPTO is a written notification that a patent application has cleared internal review and is pending issuance.
News For NVIV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
08:04 EDTNVIVInvivo Therapeutics announces UPMC as clinical side in IDE pilot study
Subscribe for More Information
November 21, 2014
08:02 EDTNVIVInvivo Therapeutics names fifth clinical site for neuro-spinal scoffold study
InVivo Therapeutics Holdings announced that the Oregon Health & Science University in Portland, OR is the fifth clinical site in the company’s ongoing IDE pilot study of its Neuro-Spinal Scaffold in patients with acute spinal cord injury. OHSU is a nationally prominent research university and Oregon’s only public academic health center, seeing nearly one million patients every year. Ahmed Raslan, MD, an Assistant Professor of Neurological Surgery at OHSU, will be the study’s Principal Investigator at that site. On October 15, InVivo announced enrollment of its first patient at Barrow Neurological Institute in Phoenix, Arizona. Mark Perrin, InVivo’s CEO, said, “We continue to bring great centers into our study and are delighted to have Dr. Raslan and OHSU join us. OHSU and the other centers will be able to enroll the next subject following the three-month observation period for first patient.” This is the company’s first clinical study of its investigational degradable polymer Neuro-Spinal Scaffold. The IDE pilot study has been approved by the U.S. FDA and is intended to capture preliminary safety and effectiveness data of the Neuro-Spinal Scaffold in five subjects with acute thoracic spinal cord injury. InVivo then expects to conduct a pivotal study to obtain FDA approval to commence commercialization under a Humanitarian Device Exemption.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use